Notal Vision’s Post

🔍 A recent study unveils that patients with neovascular age-related macular degeneration who underwent long-term treatment with a refillable port delivery system (PDS) containing ranibizumab maintained their vision without needing supplemental treatments between refills over 3 years. 👉 Learn more about these promising findings presented by Dr. David Massop in this article from Medscape by Richard Mark Kirkner #AMD #Ophthalmology #HealthcareInnovation #EyeHealth #EyeSurgery #Biotech #Medtech #Lifescience

Ophthopedia Update:Efficacy and Safety of Lotilaner Ophthalmic Solution (0.25%) for the Treatment of Demodex Blepharitis: A GRADE Assessed Systematic Review and Meta-Analysis of Observational & Experimental Studies: This review aims to assess the safety and efficacy of Lotilaner in the treatment of Demodex Blepharitis. #Ophthalmology #Ophthotwitter #Scicomm

Ophthopedia Update:The role of topical insulin on ocular surface restoration: A review: Corneal epithelial defects are one of the most common ocular disorders.Restoring corneal integrity is crucial to reduce pain and regain function,but in cases of neurotrophic or desensitized corneas,healing can be significantly delayed.Treating neurotrophic corneas is challenging for ophthalmologists,and surgical intervention is often indicated to manage refractory cases that are unresponsive to medical therapy.Over the last decade,as more expensive therapeutics reach the market,topical insulin has returned to the forefront as an affordable option to improve corneal wound healing.There is still a paucity of data on the use and the efficacy of topical insulin,with no consensus regarding its indications,preparation,or posology.Here we review the literature on topical insulin for corneal and ocular surface pathologies,with a focus on the current evidence,its mechanisms of action,and its safety profile.Additionally,we share our experience in the field and provide a potential framework for future research. #Ophthalmology #Eye #Ophthotwitter

Decreasing vitamin A dimerization may be a promising treatment avenue for treating geographic atrophy (#GA). In his presentation at #Retina Subspecialty Day at the American Academy of Ophthalmology meeting, alex melamud, MD, unveiled topline results from the phase 3 SAGA study investigating the efficacy, safety and pharmacokinetics of oral #gildeuretinol, a form of deuterated vitamin A, in patients with GA. The randomized, double-masked, placebo-controlled study assigned a total of 198 patients to treatment with gildeuretinol (135 patients) or placebo (43 patients), 70% of whom completed the study. The primary efficacy endpoint was the rate of lesion growth at 24 months, with secondary endpoints including low-luminance visual acuity and best corrected VA. A pre-specified sensitivity analysis demonstrated a statistically significant 15.3% reduction in lesion growth rate from 6 to 24 months. Patients treated with gildeuretinol also saw a reduced loss of vision compared with those in the placebo cohort, with 4.4 fewer ETDRS letters lost overall. https://bit.ly/3Yyn8di Pic (c) Retinal Physician #ophthalmology #optometry #vision #AMD #dryAMD #MacularDegeneration #drusen

Ophthopedia Update:Intravitreal Infliximab for the Treatment of Proliferative Vitreoretinopathy (FIXER): A Randomized Controlled Phase 2 Trial: To study the safety and efficacy of intravitreal infliximab administered at the conclusion of pars plana vitrectomy (PPV) in the treatment of proliferative vitreoretinopathy (PVR) associated with rhegmatogenous retinal detachment (RRD). #Ophthalmology #Retina #Ophthotwitter

🔍 Exciting Breakthrough in Glaucoma Care: MediPrint Ophthalmics' Drug-Eluting Contact Lens Shows Positive Results MediPrint Ophthalmics has announced promising Phase 2b trial results for its innovative 3D-printed, drug-eluting contact lens, LL-BMT1, designed to treat mild to moderate glaucoma. The trial showed that LL-BMT1 provides effective intraocular pressure (IOP) reduction with just six lens insertions over three weeks, an 86% reduction in treatment frequency compared to daily eye drops. Patients also reported enhanced comfort and a 40% reduction in dry eye symptoms, thanks to the hyaluronic acid integrated into the lens. 🔗 Learn more about this innovative glaucoma treatment: https://lnkd.in/d6-vumTu #Glaucoma #ClinicalTrial #ContactLens #Ophthalmology #Innovation #EyeHealth

Cornea Update: A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study: Purpose: To assess the efficacy, safety, and tolerability of a topical water-free cyclosporine A formulation (CyclASol 0.1% ophthalmic solution) in comparison with vehicle for the treatment of dry eye disease (DED). Methods: Three hundred twenty-eight patients were enrolled in this prospective, 12-week, multicenter, randomized, double-masked, confirmatory, vehicle-controlled clinical study. After a 2-week run-in period, eligible DED patients were randomized 1:1 to either CyclASol 0.1% or vehicle twice daily. The primary efficacy endpoint was change from baseline in total corneal fluorescein staining (National Eye Institute scale), and the second hierarchical primary efficacy endpoint was change from baseline in the Ocular Surface Disease Index score, both at 4 weeks. Secondary efficacy and safety assessments included conjunctival lissamine green staining (Oxford scale), visual analog scales for dry eye symptoms, and adverse event. Results: Treatment with CyclASol 0.1% was superior to vehicle in the primary endpoint: total corneal fluorescein staining at week 4 (Δ −0.8; 95% confidence interval, −1.3 to −0.4; P = 0.0002, analysis of covariance). This difference had already reached statistical significance after 2 weeks and was maintained throughout the study. The study did not statistically meet its second hierarchically tested primary endpoint: Ocular Surface Disease Index score (P = 0.2634). However, CyclASol 0.1% treatment showed statistically significant improvement compared with that of vehicle in the eye dryness score at week 4 (Δ −4.783; 95% confidence interval, −9.129 to −0.438; P = 0.0311). Conclusions: CyclASol 0.1% was effective in treating signs and symptoms of DED. It significantly reduced corneal and conjunctival staining and improved ocular dryness compared with vehicle. CyclASol 0.1% was safe and showed excellent tolerability. http://dlvr.it/TG9swp #Cornea #MostPopularArticles #Ophthalmology

Ophthopedia Update:Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension: Evaluate the safety and intraocular pressure (IOP)-lowering efficacy of two models of the travoprost intraocular implant (fast-eluting [FE-implant] and slow eluting [SE-implant]) from one of two pivotal trials (GC-010). #Ophthalmology #ophthotwitter #eyecare

March 10-16th is World Glaucoma Week and Lions Vision Trials would like to take this opportunity to put the spotlight on Glaucoma. The eye naturally produces, and naturally drains, a liquid called aqueous humour; a problem with the drainage of this aqueous humour will increase the intraocular pressure which can damage the optic nerve and cause permanent loss of vision. This is Glaucoma. Our Ophthalmologists and Scientists at the Lions Eye Institute have been instrumental in developing new treatments for Glaucoma. Professor Dao-Yi Yu and Prof William Morgan led the development of a microfistula tube, now known as the Xen® Gel Stent Implant, which is less invasive and results in faster recovery times for patients. The microfistula tube is implanted using a needle-type implanter in the space between the eye’s anterior chamber and the conjunctiva, the tissue covering the white part of the eye. This allows excess fluid to drain from the eye and thereby lower intraocular pressure. After successful FDA sponsored Phase 1 and Phase 2 studies in 2009 and 2010, full FDA approval for the Xen® Gel Stent was granted in 2016, with TGA approval soon following in 2018. The Xen® Gel Stent has now been implanted in more than 100,000 patients worldwide. Image supplied from: www.glaucoma.org.au; www.xengelstent.com #glaucomaweek #savingsight #glaucoma #opththalmology #eyehealth #clinicaltrials #LionsEyeInstitute #visioncare #lionsvisiontrials #perth #research

Optimizing Indocyanine Green Dosage for Near-Infrared Fluorescence Perfusion Assessment in Bowel Anastomosis: A Prospective, Systematic Dose-Ranging Study Background: Indocyanine green (ICG) near-infrared fluorescence (NIRF) has emerged as a promising technique for visualizing tissue perfusion. However, within the wide range of dosages and imaging conditions currently being applied, the optimal dosage of ICG remains unclear. This study aimed to investigate the feasibility and implications of implementing lower dosages of ICG than commonly used for visual and quantitative perfusion assessment in a standardized setting. Methods: A prospective single-center cohort study was conducted on patients undergoing ileostomy reversal by hand-sewn anastomosis. ICG-NIRF visualization was performed before (T1) and after (T2) anastomosis with one of four different dosages of ICG (5 mg, 2.5 mg, 1.25 mg, or 0.625 mg) and recorded. Postoperatively, each visualization was evaluated for signal strength, completeness, and homogeneity of fluorescence. Additionally, perfusion graphs were generated by a software-based quantitative perfusion assessment, allowing an analysis of perfusion parameters. Statistical analysis comparing the effect of the investigated dosages on these parameters was performed. Results: In total, 40 patients were investigated. Visual evaluation demonstrated strong, complete, and homogeneous fluorescence signals across all dosages. Perfusion graph assessment revealed a consistent shape for all dosages (ingress followed by egress phase). While the average signal intensity decreased with dosage, it was sufficient to enable perfusion assessment even at the lowest dosages of 1.25 mg and 0.625 mg of ICG. The baseline intensity at T2 (the second intraoperative visualization) significantly decreased with dosage. The slope of the egress phase steepened with decreasing dosage. Conclusions: Lower dosages of ICG were sufficient for intraoperative perfusion assessment, while causing lower residual fluorescence and quicker egress in subsequent visualizations. https://lnkd.in/eMvV8sik Leonard Lobbes M.D. Katharina Schier Kasper Tiebie Nelly Scheidel, Ioannis Pozios Richelle Hoveling PD Dr. med. Benjamin Weixler Quest Medical Imaging Charité - Universitätsmedizin Berlin #ICG #indocyaninegreen #guidedsurgery #fluorescenceguidedsurgery #Fluorescent #fluorescence #surgery #surgeon #imaging #thinkgreen #surgical #patients #bowel #visual #nearinfrared